πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8957047

GLA monotherapy for use in cancer treatment

IMMUNE DESIGN CORP. Β· Granted Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8952062

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatme

Jazz Pharmaceuticals, Inc. Β· Granted Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946158

Treatments of gastrointestinal disorders

IRONWOOD PHARMACEUTICALS, INC. Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946455

Semi-synthetic small molecules for the treatment parasitic disease

The Regents of the University of California Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946409

Polycyclic Ξ² lactam derivatives for the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946300

Use of rasagilline for the treatment of restless legs syndrome

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8946243

Compounds and methods for the treatment of viral infection

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8940301

Breast tumor treatment with anti-CXCR1 compositions

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8937060

1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention

Addex Pharma, S.A. Β· Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8937178

Phthalazinone compounds and methods for the treatment of cystic fibrosis

Flatley Discovery Lab, LLC Β· Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8937099

N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated

SENTIENT LIFESCIENCES, INC. Β· Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8936941

Compositions useful for cancer detection and treatment, a cancer stem cell model, and meth

The Board of Regents of the University of Oklahoma Β· Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8932588

Treatment of cancer involving mutated KRAS or BRAF genes

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8933216

Immunosuppression compound and treatment method

Sarepta Therapeutics, Inc. Β· Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8933030

Treatments for gastrointestinal disorders

IRONWOOD PHARMACEUTICALS, INC. Β· Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8932060

Dental treatment method

KURARAY NORITAKE DENTAL INC. Β· Granted Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8927495

Use of GnRH and analogs thereof for the prevention and treatment of pet ferret adrenocorti

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8927030

Use of nitrite salts for the treatment of cardiovascular conditions

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Jan 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8921340

Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases o

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8920800

Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

Five Prime Therapeutics, Inc. Β· Granted Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8916603

Methods for treatment with bucindolol based on genetic targeting

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Dec 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8912175

Topical compositions for treatment of skin conditions

Molecular Design International, Inc. Β· Granted Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8912214

Use of Chk2 kinase inhibitors for cancer treatment

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8911733

Inhibition of the alternative complement pathway for treatment of traumatic brain injury,

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Dec 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted